Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,689,396 | $2,708,086 | $2,469,173 | $2,469,173 |
| - Cash | $142,148 | $374,038 | $240,943 | $409,247 |
| + Debt | $1,853 | $5,231 | $8,442 | $2,052 |
| Enterprise Value | $1,549,101 | $2,339,279 | $2,236,672 | $2,061,978 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$668 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$262,833 | -$187,526 | -$135,276 | -$236,785 |
| % Margin | – | – | – | – |
| Net Income | -$243,787 | -$235,925 | -$130,904 | -$237,312 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.53 | -1.49 | -0.86 | -1.56 |
| % Growth | -2.7% | -73.3% | 44.9% | – |
| Operating Cash Flow | -$182,936 | -$163,278 | -$114,896 | -$75,420 |
| Capital Expenditures | $0 | -$117 | -$511 | -$817 |
| Free Cash Flow | -$182,936 | -$163,395 | -$115,407 | -$76,237 |